Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: Results of a 3-month non-interventional study

Current Medical Research and Opinion

Volumn 27, Issue SUPPL. 2, 2011, Pages 35-44

  Wolff, Christian ^a   Alfred, Adam ^b   Lindermller, Anton ^b   Rettig, Klaus ^c   Mattejat, Fritz ^c   Gerwe, Martin ^d   Slawik, Lara ^d   Schuble, Barbara ^e  

^a Private Practice   (Germany)

^b Private Practice   (Germany)

^c GEM Meerbusch ^*  (Germany)

^d Janssen   (Germany)

^e Medical Affairs EMEA   (Germany)

Author keywords

ADHD; Children; Extended release methylphenidate; Non interventional study

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ANOREXIA; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; BRONCHITIS; CAREGIVER; CHILD; CHILD BEHAVIOR; CHILDREN GLOBAL ASSESSMENT SCALE; CONNERS PARENT RATING SCALE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; FATIGUE; FEMALE; HOUSEHOLD; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL CONCENTRATION; MULTICENTER STUDY; NERVOUSNESS; PATIENT SATISFACTION; PERSONALITY DISORDER; PLAY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS; RATING SCALE; SIDE EFFECT; SLEEP QUALITY; SOCIAL INTERACTION; SUICIDE ATTEMPT; SYMPTOM; TIC; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION; VITAL SIGN; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; MALE; METHYLPHENIDATE; OSMOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SLEEP; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 80053606958     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.601733     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention. Attention-Deficit/ Hyperactivity Disorder. Data & Statistics in the United States. Available at: http://www.cdc.gov/ncbddd/adhd/data.html [Last accessed 20 June 2011]
2. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry 2010; 19:325-40
3. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006;15:2119-38
4. Biederman J, Faraone SV. Attention deficit hyperactivity disorder. Lancet 2005;366:237-48
5. Danckaerts M, Sonuga-Barke EJS, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2010;19:83-105
6. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003;60:204-11 (Pubitemid 36173129)
7. Remschmidt H, Hoare P, Ettrich C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH: results of a 3-week, open-label study. Eur Child Adolesc Psychiatry 2005;14: 297-304
8. Niederkirchner K, Slawik L, Wermelskirchen D, et al. Transitioning to OROS methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Rev Neurother 2011;11:499-508
9. Mattejat F, Jungmann J, Meusers M, et al. Das Inventar zur Erfassung der Lebensqualitä t bei Kindern und Jugendlichen (ILK)-Eine Pilotstudie. Zeitschrift fü r Kinder-und Jugendpsychiatrie 1998;26:174-82 (Pubitemid 28391546)
10. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998;59 (Suppl 7):24-30 (Pubitemid 28317219)
11. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999; 46:857-70 (Pubitemid 29477877)
12. Conners CK, Sitarenios G, Parker JD, et al. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-68 (Pubitemid 28359774)
13. Mattejat F, Remschmidt H. Das Inventar zur Erfassung der Lebensqualitä t bei Kindern und Jugendlichen (ILK) (The inventory of life quality in children and adolescents ILC). Bern: Verlag Hans Huber, 2006
14. Mattejat F, Simon B, Kö nig U, et al. Lebensqualitä t bei psychisch kranken Kindern und Jugendlichen. Zeitschrift fü r Kinder-und Jugendpsychiatrie 2003;31:293-303
15. Jozefiak T, Larsson B, Wichstrøm L, et al. Quality of Life as reported by school children and their parents: a cross-sectional survey. Health Qual Life Outcome 2008;6:34-45
16. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31 (Pubitemid 13015019)
17. Dö pfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of oncea-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I93-101
18. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extendedrelease methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004;113(3 Pt 1):e206-16
19. Sonuga-Barke EJ, Swanson JM, Coghill D, et al. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004;4:28